The detection and measurement of locomotor deficits in a transgenic mouse model of Huntington's disease are task- and protocol-dependent: Influence of non-motor factors on locomotor function

Brain Research Bulletin

Volumn 78, Issue 6, 2009, Pages 347-355

  Pallier, Patrick N ^a   Drew, Cheney J G ^a   Morton, A Jennifer ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Digigait; Footprint analysis; Motor function; R6 2 mice; Rotarod

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FATIGUE; FEMALE; HUNTINGTON CHOREA; LOCOMOTION; MOTOR PERFORMANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; ROTAROD TEST; TASK PERFORMANCE; VELOCITY;

ANIMALS; BODY WEIGHT; DISEASE MODELS, ANIMAL; FEMALE; GAIT; HUNTINGTON DISEASE; LOCOMOTION; MICE; MICE, TRANSGENIC; MOTOR ACTIVITY; MOTOR SKILLS; MOVEMENT DISORDERS; MUSCLE FATIGUE; POSTURAL BALANCE; ROTAROD PERFORMANCE TEST; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 58949105069     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2008.10.007     Document Type: Article

References (52)

1. Amende I., Kale A., McCue S., Glazier S., Morgan J.P., and Hampton T.G. Gait dynamics in mouse models of Parkinson's disease and Huntington's disease. J. Neuroeng. Rehabil. 25 (2005) 2-20
2. Bates G.P., Harper P.S., and Jones L. Huntington's Disease. 3rd ed. (2002), Oxford University Press, Oxford
3. Beal M.F., Brouillet E., Jenkins B.G., Ferrante R.J., Kowall N.W., Miller J.M., Storey E., Srivastava R., Rosen B.R., and Hyman B.T. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J. Neurosci. 13 (1993) 4181-4192
4. Bhidayasiri R., and Truong D.D. Chorea and related disorders. Postgrad. Med. J. 80 (2004) 527-534
5. Bilney B., Morris M.E., Churchyard A., Chiu E., and Georgiou-Karistianis N. Evidence for a disorder of locomotor timing in Huntington's disease. Mov. Disord. 20 (2005) 51-57
6. Bilney B., Morris M.E., and Denisenko S. Physiotherapy for people with movement disorders arising from basal ganglia dysfunction. N. Z. J. Psychol. 31 (2003) 94-100
7. Bilney B., Morris M.E., and Perry A. Effectiveness of physiotherapy, occupational therapy, and speech pathology for people with Huntington's disease: a systematic review. Neurorehabil. Neural Repair 17 (2003) 12-24
8. Bolivar V.J., Manley K., and Messer A. Exploratory activity and fear conditioning abnormalities develop early in R6/2 Huntington's disease transgenic mice. Behav. Neurosci. 117 (2003) 1233-1242
9. Brandt J., Strauss M.E., Larus J., Jensen B., Foltstein S.E., and Foltstein M.F. Clinical correlates of dementia and disability in Huntington's disease. J. Clin. Neuropsychol. 6 (1984) 401-412
10. Busse M.E., and Rosser A.E. Can directed activity improve mobility in Huntington's disease?. Brain Res. Bull. 72 (2007) 172-174
11. Carter R.J., Hunt M.J., and Morton A.J. Environmental stimulation increases survival in mice transgenic for exon 1 of the Huntington's disease gene. Mov. Disord. 15 (2000) 925-937
12. Carter R.J., Lione L.A., Humby T., Mangiarini L., Mahal A., Bates G.P., Dunnett S.B., and Morton A.J. Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J. Neurosci. 19 (1999) 3248-3257
13. Cepeda C., Hurst R.S., Calvert C.R., Hernandez-Echeagaray E., Nguyen O.K., Jocoy E., Christian L.J., Ariano M.A., and Levine M.S. Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease. J. Neurosci. 23 (2003) 961-969
14. Ciamei A., and Morton A.J. Rigidity in social and emotional memory in the R6/2 mouse model of Huntington's disease. Neurobiol. Learn. Mem. 89 (2008) 533-544
15. Currà A., Agostino R., Galizia P., Fittipaldi F., Manfredi M., and Berardelli A. Sub-movement cueing and motor sequence in patients with Huntington's disease. Clin. Neurophysiol. 111 (2000) 1184-1190
16. Delval A., Krystkowiak P., Blatt J.-L., Labyt E., Bourriez J.-L., Dujardin K., Destée A., Derambure P., and Defebvre L. A biomechanical study of gait initiation in Huntington's disease. Gait Posture 25 (2007) 279-288
17. Delval A., Krystkowiak P., Delliaux M., Dujardin K., Blatt J.-L., Destée A., Derambure P., and Defebvre L. Role of attentional resources on gait performance in Huntington's disease. Mov. Disord. 23 (2008) 684-689
18. Dunnett S.B., Carter R.J., Watts C., Torres E.M., Mahal A., Mangiarini L., Bates G., and Morton A.J. Striatal transplantation in a transgenic mouse model of Huntington's disease. Exp. Neurol. 154 (1998) 31-40
19. 10 and remacemide in transgenic mouse models of Huntington's disease. J. Neurosci. 22 (2002) 1592-1599
20. Ferrante R.J., Andreassen O.A., Jenkins B.G., Dedeoglu A., Kuemmerle S., Kubilus J.K., Kaddurah-Daouk R., Hersch S.M., and Beal M.F. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J. Neurosci. 20 (2000) 4389-4397
21. Ferrante R.J., Kubilus J.K., Lee J., Ryu H., Beesen A., Zucker B., Smith K., Kowall N.W., Ratan R.R., Luthi-Carter R., and Hersch S.M. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J. Neurosci. 23 (2003) 9418-9427
22. Foltstein S.E., Jensen B., Leigh R.J., and Foltstein M. The measurement of abnormal movement: methods developed for Huntington's disease. Neurobehav. Toxicol. Teratol. 5 (1983) 605-609
23. Hampton T.G., Stasko M.R., Kale A., Amende I., and Costa A.C. Gait dynamics in trisomic mice: quantitative neurological traits of Down syndrome. Physiol. Behav. 82 (2004) 381-389
24. Hickey M.A., Gallant K., Gross G.G., Levine M.S., and Chesselet M.F. Early behavioral deficits in R6/2 mice suitable for use in preclinical drug testing. Neurobiol. Dis. 20 (2005) 1-11
25. Higgins D.S.J. Chorea and its disorders. Neurol. Clin. 19 (2001) 707-722 vii
26. Hockly E., Cordery P.M., Woodman B., Mahal A., van Dellen A., Blakemore C., Lewis C.M., Hannan A.J., and Bates G.P. Environmental enrichment slows disease progression in R6/2 Huntington's disease mice. Ann. Neurol. 51 (2002) 235-242
27. Hockly E., Woodman B., Mahal A., Lewis C.M., and Bates G. Standardization and statistical approaches to therapeutic trials in the R6/2 mouse. Brain Res. Bull. 61 (2003) 469-479
28. Johnson K.A., Cunnington R., Bradshaw J.L., Chiu E., and Iansek R. Effect of an attentional strategy on movement-related potentials recorded from subjects with Huntington's disease. Mov. Disord. 17 (2002) 998-1003
29. Kale A., Amende I., Meyer G.P., Crabbe J.C., and Hampton T.G. Ethanol's effects on gait dynamics in mice investigated by ventral plane videography. Alcohol Clin. Exp. Res. 28 (2004) 1839-1848
30. Kang H.G., and Dingwell J.B. Separating the effects of age and walking speed on gait variability. Gait Posture 27 (2008) 572-577
31. Klapstein G.J., Fisher R.S., Zanjani H., Cepeda C., Jokel E.S., Chesselet M.F., and Levine M.S. Electrophysiological and morphological changes in striatal spiny neurons in R6/2 Huntington's disease transgenic mice. J. Neurophysiol. 86 (2001) 2667-2677
32. Koller W.C., and Trimble J. The gait abnormality of Huntington's disease. Neurology 35 (1985) 1450-1454
33. Kremer B. Clinical neurology of Huntington's disease. In: Bates G.P., Harper P.S., and Jones L. (Eds). Huntington's Disease (2002), Oxford University Press, Oxford 28-61
34. Lione L.A., Carter R.J., Hunt M.J., Bates G.P., Morton A.J., and Dunnett S.B. Selective discrimination learning impairments in mice expressing the human Huntington's disease mutation. J. Neurosci. 19 (1999) 10428-10437
35. Lüesse H.-G., Schiefer J., Spruenken A., Puls C., Block F., and Kosinski C.M. Evaluation of R6/2 HD transgenic mice for therapeutic studies in Huntington's disease: behavioral testing and impact of diabetes mellitus. Behav. Brain Res. 126 (2001) 185-195
36. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S.W., and Bates G.P. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87 (1996) 493-506
37. Morton A.J., Hunt M.J., Hodges A.K., Lewis P.D., Redfern A.J., Dunnett S.B., and Jones L. A combination drug therapy improves cognition and reverses gene expression changes in a mouse model of Huntington's disease. Eur. J. Neurosci. 21 (2005) 855-870
38. Morton A.J., Skillings E., Bussey T.J., and Saksida L.M. Measuring cognitive deficits in disabled mice using an automated interactive touchscreen system. Nat. Methods 3 (2006) 767
39. Morton A.J., Wood N.I., Hastings M.H., Hurelbrink C., Barker R.A., and Maywood E.S. Disintegration of the sleep-wake cycle and circadian timing in Huntington's disease. J. Neurosci. 25 (2005) 157-163
40. Pallier P.N., Maywood E.S., Zheng Z., Chesham J.E., Inyushkin A.N., Dyball R., Hastings M.H., and Morton A.J. Pharmacological imposition of sleep slows cognitive decline and reverses dysregulation of circadian gene expression in a transgenic mouse model of Huntington's disease. J. Neurosci. 27 (2007) 7869-7878
41. Rebec G.V., Barton S.J., and Ennis M.D. Dysregulation of ascorbate release in the striatum of behaving mice expressing the Huntington's disease gene. J. Neurosci. 22 (2002) RC202
42. Regnaux J.P., Robertson J., Ben Smail D., Daniel O., and Bussel B. Human treadmill walking needs attention. J. Neuroeng. Rehabil. 3 (2006) 1-7
43. Reynolds D.S., Carter R.J., and Morton A.J. Dopamine modulates the susceptibility of striatal neurons to 3-nitropropionic acid in the rat model of Huntington's disease. J. Neurosci. 18 (1998) 10116-10127
44. Schiefer J., Sprünken A., Puls C., Lüesse H.-G., Milkereit A., Milkereit E., Johann V., and Kosinski C.M. The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington's disease. Brain Res. 1019 (2004) 246-254
45. 10 formulations in Huntington's disease mice. Biochim. Biophys. Acta 1762 (2006) 616-626
46. Sprengelmeyer R., Lange H., and Homberg V. The pattern of attentional deficits in Huntington's disease. Brain 118 (1995) 145-152
47. Stack E.C., Kubilus J.K., Smith K., Cormier K., Del Signore S.J., Guelin E., Ryu H., Hersch S.M., and Ferrante R.J. Chronology of behavioral symptoms and neuropathological sequela in R6/2 Huntington's disease transgenic mice. J. Comp. Neurol. 490 (2005) 354-370
48. Stolze H., Kuhtz-Buschbeck J.P., Mondwurf C., Boczek-Funcke A., Jöhnk K., Deuschl G., and Illert M. Gait analysis during treadmill and overground locomotion in children and adults. Electroencephalogr. Clin. Neurophysiol. 105 (1997) 490-497
49. Turmaine M., Raza A., Mahal A., Mangiarini L., Bates G.P., and Davies S.W. Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 8093-8097
50. Wooley C.M., Sher R.B., Kale A., Frankel W.N., Cox G.A., and Seburn K.L. Gait analysis detects early changes in transgenic SOD1(G93A) mice. Muscle Nerve 32 (2005) 43-50
51. Woollacott M., and Shumway-Cook A. Attention and the control of posture and gait: a review of an emerging area of research. Gait Posture 16 (2002) 1-14
52. Yogev-Seligmann G., Hausdorff J.M., and Giladi N. The role of executive function and attention in gait. Mov. Disord. 23 (2008) 329-342